<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573233</url>
  </required_header>
  <id_info>
    <org_study_id>PDY14192</org_study_id>
    <secondary_id>2015-001572-22</secondary_id>
    <secondary_id>U1111-1170-7168</secondary_id>
    <nct_id>NCT02573233</nct_id>
  </id_info>
  <brief_title>Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma</brief_title>
  <acronym>EXPEDITION</acronym>
  <official_title>An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in patients
      with persistent asthma.

      Secondary Objective:

      To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration for each patient is between approximately 29 and maximum of 30
      weeks, consisting of a screening period of 5 weeks and optional up to 7 additional days, a
      treatment period of 12 weeks, and a post-treatment period of 12 weeks.

      Patients who complete the treatment period may be eligible to participate in an open-label
      extension study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 27, 2016</start_date>
  <completion_date type="Actual">January 3, 2018</completion_date>
  <primary_completion_date type="Actual">January 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in number of inflammatory cells in the bronchial submucosa per square millimeter</measure>
    <time_frame>At 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in mucin-stained area in the bronchial submucosa per square millimeter</measure>
    <time_frame>At 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in exhaled nitric oxide</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with antidrug antibodies</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dupilumab every 2 weeks (loading dose with a double dose) added to current controller medications (eg, fluticasone propionate/salmeterol, budesonide/formoterol, mometasone furoate/formoterol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for dupilumab) every 2 weeks (loading dose with a double dose) added to current controller medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dupilumab SAR231893/REGN668</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate and salmeterol</intervention_name>
    <description>Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide and formoterol</intervention_name>
    <description>Pharmaceutical form:inhalation aerosol Route of administration: inhaled</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Symbicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate and formoterol</intervention_name>
    <description>Pharmaceutical form:inhalation aerosol Route of administration: inhaled</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dulera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female adults with a physician diagnosis of persistent asthma for ≥12 months.

          -  Existing treatment with medium to high dose inhaled corticosteroids in combination
             with a long-acting beta agonist for at least 3 months with a stable dose ≥1 month
             prior to Visit 1 (Screening Visit).

               -  Treatment with a third asthma controller for at least 3 months with a stable dose
                  ≥1 month prior to Visit 1 is allowed.

          -  Pre-bronchodilator forced expiratory volume (FEV1) 55 to 85% of predicted normal.

        Exclusion criteria:

          -  Patients &lt;18 years or &gt;65 years.

          -  Fractional exhaled nitric oxide (FeNO) &lt;26 ppb at Visit 1 (Screening Visit).

          -  Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary
             fibrosis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss Syndrome])
             which may impair lung function.

          -  A patient who experiences an asthma exacerbation that results in emergency treatment,
             hospitalization due to asthma, or treatment with systemic steroids at any time from 1
             month prior to Visit 1.

          -  A patient who has experienced an upper or lower respiratory tract infection within the
             4 weeks prior to Visit 1.

          -  Evidence of lung disease(s) other than asthma.

          -  Previous smoker (smoking history &gt;10 pack-years) or current smoker (within 6 months
             prior to Visit 1).

          -  Comorbid disease that might interfere with the evaluation of investigational medicinal
             product or conduct of study procedures (eg, bronchoscopy).

          -  Anti-immunoglobulin E (IgE) therapy (omalizumab) or any other biologic therapy within
             6 months of Visit 1.

          -  Exposure to another investigative study medication within a time period prior to Visit
             1 that is less than 5 half-lives of the study medication.

          -  Treatment with systemic (oral or injectable) corticosteroids within 28 days of Visit
             1.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840402</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840403</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840401</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840404</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840028</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124012</name>
      <address>
        <city>Montreal</city>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124018</name>
      <address>
        <city>Sainte Foy</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208002</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208001</name>
      <address>
        <city>København Nv</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276013</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276011</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276012</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752001</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826010</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826009</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Not yet available for request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

